Loading…
Fortress Biotech, Inc. is projected to rise to $3.50 by 2027, a +12% move from its current price of $3.13. FBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.02 | $3.13 | $3.24 | -0.03% |
| Aug 6 | $2.98 | $3.13 | $3.29 | -0.05% |
| Aug 7 | $2.94 | $3.13 | $3.32 | -0.08% |
| Aug 8 | $2.92 | $3.13 | $3.35 | -0.10% |
| Aug 9 | $2.89 | $3.13 | $3.38 | -0.13% |
| Aug 10 | $2.87 | $3.13 | $3.41 | -0.15% |
| Aug 11 | $2.85 | $3.12 | $3.43 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.85 | $3.12 | $3.43 | -0.18% |
| Week 2 | $2.74 | $3.12 | $3.56 | -0.35% |
| Week 3 | $2.65 | $3.11 | $3.66 | -0.53% |
| Week 4 | $2.58 | $3.11 | $3.74 | -0.71% |
| Week 5 | $2.52 | $3.10 | $3.82 | -0.88% |
| Week 6 | $2.47 | $3.10 | $3.89 | -1.06% |
| Week 7 | $2.42 | $3.09 | $3.95 | -1.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia.
The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Fortress Biotech, Inc. is a US- and internationally active biopharmaceutical company with a diverse pipeline of products across dermatology, infectious disease, and specialty indications. The stock is currently trading at $3.13 per share with a market capitalization of $103.98M and a rank of 4126.
The current price and market position form the baseline for the forecasted trajectory shown in the year-by-year outlook. The forecast envisions a path of rising averages over time, with notable uplift in the later years including 2040 and 2050.
A major floor 29.1% below — a decisive break under it would weaken the trend.
The nearest floor, 11.8% below — buyers have tended to step in here.
The nearest ceiling, 19.2% above — a clean break opens room to run.
A major ceiling 33.4% above — clearing it would confirm fresh momentum.
Key FBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.29 | Sell | $3.27 | Sell |
| MA 10 | $3.36 | Sell | $3.32 | Sell |
| MA 20 | $3.33 | Sell | $3.29 | Sell |
| MA 50 | $3.05 | Buy | $3.10 | Buy |
| MA 100 | $2.81 | Buy | $2.99 | Buy |
| MA 200 | $2.98 | Buy | $2.89 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.94 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -91.44 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -15.63 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.59 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 30.52 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 3.24 | Sell |
| ADX (14) | 16.22 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture shows a bullish sentiment. RSI14 is 50 and the short-term moving averages are $3.05 for the SMA50 and $2.98 for the SMA200. The stock sits above a support level of $2.76 and below a resistance at $3.73. Over the next 30 days, the price has traded in a range from $2.48 to $3.94.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.22 | $3.13 | $4.08 | 0% | Neutral | |
| $2.72 | $3.50 | $4.80 | +12% | Neutral | |
| $3.09 | $4.13 | $5.94 | +32% | Bullish | |
| $2.91 | $4.01 | $5.98 | +28% | Bullish | |
| $3.55 | $5.04 | $7.73 | +61% | Bullish | |
| $4.80 | $6.97 | $10.99 | +123% | Bullish | |
| $4.96 | $7.37 | $11.88 | +136% | Bullish | |
| $5.16 | $7.85 | $12.92 | +151% | Bullish | |
| $5.24 | $8.15 | $13.67 | +160% | Bullish | |
| $5.30 | $8.41 | $14.37 | +169% | Bullish | |
| $8.36 | $14.58 | $26.79 | +366% | Bullish | |
| $15.24 | $31.47 | $64.26 | +905% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.22 | $3.13 | $3.78 | +0.00% |
| September 2026 | $2.53 | $3.01 | $3.71 | -3.75% |
| October 2026 | $2.54 | $3.06 | $3.82 | +1.53% |
| November 2026 | $2.64 | $3.19 | $4.03 | +4.43% |
| December 2026 | $2.62 | $3.20 | $4.08 | +0.15% |
Click any year to see its month-by-month FBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FBIO is projected to trade between $2.22 and $4.08, averaging $3.13 — a potential gain of 0% from today's $3.13. A consolidation phase looks the most probable path here.
Fortress Biotech, Inc.'s 2027 outlook centres on $3.50, within a $2.72 to $4.80 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, FBIO could reach as high as $5.94, with a base case around $4.13 and support toward $3.09 — roughly +32% from $3.13. Buyers look set to stay in control over this stretch.
Expect FBIO to range from $2.91 to $5.98 through 2029. The $4.01 average target implies a +28% move from current prices. That is -3% versus the projected 2028 average. Momentum favours further upside here.
The FBIO price prediction for 2030 points to an average of $5.04 (low $3.55, high $7.73) — a potential gain of +61% on today's $3.13. Buyers look set to stay in control over this stretch.
In 2031, FBIO is projected to trade between $4.80 and $10.99, averaging $6.97 — a potential gain of +123% from today's $3.13. That is up +39% on the projected 2030 average. Momentum favours further upside here.
Fortress Biotech, Inc.'s 2032 outlook centres on $7.37, within a $4.96 to $11.88 range. That is up +6% on the projected 2031 average. That marks a +136% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, FBIO could reach as high as $12.92, with a base case around $7.85 and support toward $5.16 — roughly +151% from $3.13. Momentum favours further upside here.
Expect FBIO to range from $5.24 to $13.67 through 2034. The $8.15 average target implies a +160% move from current prices. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The FBIO price prediction for 2035 points to an average of $8.41 (low $5.30, high $14.37) — a potential gain of +169% on today's $3.13. Momentum favours further upside here.
In 2040, FBIO is projected to trade between $8.36 and $26.79, averaging $14.58 — a potential gain of +366% from today's $3.13. That is up +73% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Fortress Biotech, Inc.'s 2050 outlook centres on $31.47, within a $15.24 to $64.26 range. That is up +116% on the projected 2040 average. That marks a +905% change versus current levels. Momentum favours further upside here.
Investing $1,000 in FBIO today (≈ 319.488818 FBIO) could be worth
$10,054.36
+$9,054.36 (+905%) by 2050 · US Dollar
Based on the average projected FBIO price of $31.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FBIOwould be worth at today's price.
$1,000 invested in FBIO on Jul 31, 2025 (≈ 540.540534 FBIO) would be worth
$1,691.89
+$691.89 (+69.2%) today · 1.69× · US Dollar
Based on a FBIO entry price of $1.85 vs. today's $3.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.34 | $937.13 | -6.3% |
| 1 month ago | $3.09 | $1,012.95 | +1.3% |
| 3 months ago | $2.33 | $1,343.35 | +34.3% |
| 6 months ago | $3.15 | $993.65 | -0.6% |
| 1 year ago | $1.85 | $1,691.89 | +69.2% |
| All time (5.0y) ago | $48.45 | $64.6 | -93.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FBIO forecast.
Our base-case forecast reaches $6.30 around 2031.
Implied market cap at $6.30: $209.28M
The multi-year forecast points to a bullish trajectory with a meaningful upside from the current level. The 2026 average is $3.13, with a 2026 min of $2.22 and max of $4.08. By 2030, the average rises to $5.04, with a projected ROI of 61.1 and a bullish sentiment continuing through 2031–2050.
In 2040, the average is $14.58 with a 365.8 ROI, and by 2050 the average reaches $31.47 with a 905.4 ROI. The sequence of yearly averages from 2027 onward generally trends higher, culminating in a very strong long-term outlook. These figures are estimates and carry inherent uncertainty and risk; they are not guarantees of future performance.
Tap a question to reveal the answer.
The 2030 average price is $5.04 per share with a projected ROI of 61.1. (Min 3.56, Avg 5.04, Max 7.74; sentiment bullish)
The forecast shows a neutral stance in 2026 and bullish sentiment from 2027 onward, with substantial upside by 2030 and beyond (2030 avg $5.04, 2040 avg $14.58, 2050 avg $31.47). These are estimates, not guarantees.
Yes, the 2031 maximum forecast is $11.00, indicating the potential to exceed $10 in the outlook. For reference, 2031 max is $11.00 and 2030 average is $5.04.
The 2026 forecast shows a min of $2.22, an average of $3.13, and a max of $4.08, with sentiment listed as neutral.
The 2040 forecast shows a min of $8.36, an average of $14.58, and a max of $26.79, with a ROI of 365.8 and sentiment bullish.
Fortress Biotech, Inc. Community Discussion
0Share your Fortress Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.